Arboretum LifeSciences has emerged from stealth with $30 million in financing. The startup plans to combine diagnostics and drug development, using data from its genetic tests to inform partnerships with large pharmaceutical companies and to seed new biotech ventures.
The company's approach is described as a precision medicine strategy aimed at common diseases, rather than the rare conditions that often dominate genetic medicine. Executives say the analyses from its tests are central to both collaboration deals and the creation of new companies.
The funding and launch signal continued investor interest in platforms that generate clinical data while also building a pipeline of therapies. The specific diseases or partners were not detailed in the announcement.